Peptide Quarterly

Peptide Quarterly

Issue OneOctober 20264 features77 compounds queried

The theme of this issue

The Two Registers

Three public registers, read in one week, describe two populations that share a vocabulary and almost nothing else.

Registered studies per corpus compoundOne vertical rule per compound in the 77-compound corpus, in alphabetical order. Rule height is set by the number of registered study records the registry returns for that name, on a logarithmic scale against a maximum of 2155. A compound returning no records is drawn as a baseline mark rather than omitted.
The cover figure is the issue’s first finding, not an illustration. One rule per compound in the 77-name corpus, alphabetical, height set by how many registered studies the public trials registry returns for that name, on a logarithmic scale. 18 names return nothing. Retrieved 2026-10-13.

The leader

Three public registers were queried on consecutive days in October 2026: the United States clinical trials registry, the Federal Register, and a measured record of what is searched for. Each was asked one narrow question about the same 77 compound names. The three answers do not describe one market.

Registered development is concentrated to the point of being almost a different industry from the catalogue it is supposed to belong to. Ten names account for 8,058 of 10,992 registered study records. The lower half of the same list accounts for 102. The federal publication record, meanwhile, is barely about compounds at all: it is about who may compound, under which section of the law, from which substances. And the names carrying the heaviest public attention are, with very few exceptions, not the names carrying development.

The convenient story is one sector on one growth curve. Read together, the three registers describe two populations and the regulatory channel that connects them. This issue makes that argument in four features, each set against a different register, each one re-runnable by a reader from the query printed beside every figure it uses.

There is no market size in this issue, no growth rate and no forecast. None of those is something this desk retrieved, and this publication does not print numbers it did not retrieve.

Read the contents of Issue One

Standing departments

  • The PipelineRegistered development, counted rather than described.
  • The RegisterThe regulatory environment as the federal publication record holds it.
  • The LedgerWhat the documentary record will and will not support commercially.

What this publication is

Peptide Quarterly reports on the peptide sector as a business and a regulatory environment. It is written for people who need the shape of the sector rather than the detail of any compound: the ten names carrying registered development, the four terms carrying the regulatory record, and the gap between what is searched for and what is being developed.

It carries no advertising and no sponsored placement. It publishes no market size, no growth rate and no forecast, because this desk does not retrieve those and will not estimate them. It quotes nobody, because it has interviewed nobody. Every figure it prints is a count returned by a named public register on a stated date, and the query that produced it is printed beside it.

It publishes at most four issues a year, and only when there is a second argument worth four features. Reading the public registers side by side is the whole of the method.

More about how this is made and who it is for